Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zabofloxacin - Dong Wha Pharmaceutical

Drug Profile

Zabofloxacin - Dong Wha Pharmaceutical

Alternative Names: DW-224a; DW224aa; PB-101; Zabofloxacin hydrochloride; Zabolante; Zrumgil

Latest Information Update: 01 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong Wha
  • Developer Dong Wha Pharmaceutical; IASO Pharma
  • Class Antibacterials; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Naphthyridines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Respiratory tract infections
  • No development reported Community-acquired pneumonia

Most Recent Events

  • 01 Aug 2019 Phase III development for Respiratory tract infections is ongoing in South Korea (Dong Wha Pharmaceutical, pipeline August 2019)
  • 09 Sep 2015 No recent reports on development identified - Phase-II for Community-acquired pneumonia in South Korea (PO, capsule)
  • 01 Aug 2014 Dong Wha completes a phase III trial in Respiratory tract infections in South Korea (NCT01658020) (PO, tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top